Ligia A Pinto
Ligia A Pinto, PhD is an expert in Oncology at Leidos Biomedical Research (United States). Ligia A Pinto has authored 245 publications, the most recent in 2026, and is an investigator in 9 clinical trials. SLR score: 803 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Infectiology - Immunology - Pharmacy
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 1993 - 2026
Number : 245
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Pre-vaccine sentinel antibodies predict blunted vaccine responses. PMID 42746633 — antibody formation, vaccines, antibodies, biomarkers, vaccination, viruses, immunosuppression therapy | Cell Press Blue | 2026 | 0 |
| Circulating SARS-CoV-2 Spike IgG Antibody Levels and Avidity in Autoimmune, IBD and Transplant Cohorts: An Observational Study Following Multiple COVID-19 Vaccine Boosters. PMID 42646705 — sars-cov-2, serology, vaccines, covid-19 vaccines, vaccination, covid-19, immunity, autoimmune diseases, transplants, severe acute respiratory syndrome-related coronavirus, immunoglobulin g | Vaccines (Basel) | 2026 | 0 |
| Harmonization of Real-World Data for Vaccine-Preventable Infectious Diseases: Integration of SARS-CoV-2 Diagnostic and Serologic Data From Multiple Sources. PMID 42558864 — coronavirus, sars-cov-2, serology, laboratories, vaccines, neoplasms, covid-19, serologic tests, severe acute respiratory syndrome-related coronavirus, names, communicable diseases, transplantation | Open Forum Infect Dis | 2026 | 0 |
| Effect of malaria parasitaemia on antibody responses to single-dose and two-dose HPV vaccination: results from the DoRIS dose-reduction immunogenicity trial in Tanzanian girls. PMID 42378813 — malaria, antibody formation, vaccines, vaccination, drug tapering, alphapapillomavirus, artificial intelligence, human papillomavirus viruses | Vaccine | 2026 | 0 |
| A semi-automated ELISA workflow for SARS-CoV-2 IgG detection significantly improves throughput and reduces hands-on time. PMID 42259430 — sars-cov-2, antibodies, workflow, enzyme-linked immunosorbent assay, automation, severe acute respiratory syndrome-related coronavirus | J Immunol Methods | 2026 | 0 |
Clinical Studies 9
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 5
LeadR Networks
Main global connection map